Swiss firm to invest heavily in manufacturing for complex biological drugs

Biotech company Roche will invest CHF800 million (£550 million) into manufacturing biological medicines over the next five years.

The investment aims to meet the increasing demand for Roche’s licensed biologics – such as Perjeta (pertuzumab), which has recently been granted accelerated approval by the US Food and Drug administration for use in preoperative breast cancer. Expansion will also support a potential 39 further biologics in the development pipeline.

Around 450 new jobs will be established across sites in Penzberg, Germany, and Vacaville and Oceanside, US, as the sites’ manufacturing capacity expands. A further 50 jobs will be created in Basel, Switzerland, where a new antibody-drug conjugate (ADC) production facility will also support the growth of Roche’s first licensed ADC, Kadcyla (trastuzumab emtansine), among others under development.